Excessive levels of 6-MP can cause myelosuppression and myelotoxicity.
2.
Myelosuppression more commonly occurs in CML patients and includes : thrombocytopenia and neutropenia.
3.
Unlike other nitrogen mustards, estramustine phosphate seldom produces significant hematologic toxicity such as myelosuppression,
4.
IG reversed cyclophosphamide-induced myelosuppression in tumor-bearing animals and enhanced survival rate.
5.
The effect of recombinant human granulocyte-macrophage colony stimulating factor on chemotherapy-induced myelosuppression.
6.
These anticancer drugs have, however, some limitations due to side effects, principally myelosuppression and neurotoxicity.
7.
It can cause the symptoms of diarrhoea and myelosuppression experienced by ~ 25 % of the patients administered irinotecan.
8.
GM-CSF has been compared to G-CSF as a treatment of chemotherapy-induced myelosuppression / Neutropenia.
9.
Chemotherapy can cause myelosuppression and unacceptably low levels of white blood cells ( neutropenia ), making patients susceptible to infections and sepsis.
10.
However, doxorubicin is associated with side effects such as myelosuppression, gastrointestinal disorders, mucositis, stomatitis, cumulative cardiotoxicity and extravasation.
